zacks.com · 29 jun

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com · 25 jun

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.

zacks.com · 25 jun

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

businesswire.com · 24 jun

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent for patients who are not candidates f.

zacks.com · 24 jun

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

seekingalpha.com · 23 jun

Gilead Sciences: The Market Is Underestimating Its Growth Runway

Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy.

businesswire.com · 23 jun

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (.

zacks.com · 18 jun

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.